Relx (RELX) EBITDA (2021 - 2025)
On a quarterly basis, EBITDA rose 5.52% to $7442.3 in Q4 2025 year-over-year; TTM through Dec 2022 was $3.9 billion, a N/A change, with the full-year FY2025 number at $5115.8, up 7.03% from a year prior.
Relx (RELX) has 4 years of EBITDA data on record, last reported at $7442.3 in Q4 2025.
- EBITDA reached $7442.3 in Q4 2025 per RELX's latest filing, up from $7052.8 in the prior quarter.
- Over the last five years, EBITDA for RELX hit a ceiling of $3.9 billion in Q4 2022 and a floor of $7052.8 in Q4 2024.
- A 4-year average of $1.6 billion and a median of $1.3 billion in 2021 define the central range for EBITDA.
- Peak YoY movement for EBITDA: surged 51.38% in 2022, then increased 5.52% in 2025.
- Tracing RELX's EBITDA over 4 years: stood at $2.6 billion in 2021, then soared by 51.38% to $3.9 billion in 2022, then crashed by 100.0% to $7052.8 in 2024, then increased by 5.52% to $7442.3 in 2025.
- Business Quant data shows EBITDA for RELX at $7442.3 in Q4 2025, $7052.8 in Q4 2024, and $3.9 billion in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Relx | 81.40 Bn | 81.16 Bn | - | 7,442.28 |
| 2 | Rentokil Initial | 79.56 Bn | 78.10 Bn | - | 510.00 Mn |
| 3 | Cintas | 69.26 Bn | 69.08 Bn | 1.45 Bn | 659.90 Mn |
| 4 | Copart | 33.09 Bn | 28.01 Bn | 971.24 Mn | 388.71 Mn |
| 5 | UL Solutions | 20.56 Bn | 20.32 Bn | 381.00 Mn | 138.00 Mn |
| 6 | Global Payments | 19.88 Bn | 14.69 Bn | 1.70 Bn | -15.65 Mn |
| 7 | Rb Global | 19.08 Bn | 18.89 Bn | 869.50 Mn | 217.50 Mn |
| 8 | Aramark | 13.57 Bn | 13.16 Bn | 426.35 Mn | 219.75 Mn |
| 9 | Amentum Holdings | 5.65 Bn | 5.74 Bn | 345.00 Mn | 151.00 Mn |
| 10 | Dolby Laboratories | 5.15 Bn | 4.56 Bn | 350.90 Mn | 112.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7,442.28 |
| Dec 31, 2024 | 7,052.84 |
| Dec 31, 2022 | 3.94 Bn |
| Dec 31, 2021 | 2.60 Bn |